{
    "nct_id": "NCT02249403",
    "title": "Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type",
    "status": "COMPLETED",
    "last_update_time": "2014-09-25",
    "description_brief": "The objective of this trial was to assess the dose-response relationship of symptomatic efficacy of talsaclidine base on ADAScog and to assess safety and tolerability",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "Talsaclidine (functionally selective muscarinic M1 receptor agonist; small-molecule)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial's objective was to assess symptomatic efficacy on the ADAS-Cog (a cognitive outcome), indicating the study targeted cognitive improvement rather than a diagnostic or purely disease-modifying endpoint. \ue200cite\ue202turn0search0\ue201",
        "Act: Talsaclidine is a small-molecule, functionally selective muscarinic M1 receptor agonist developed for symptomatic (cognitive) treatment of Alzheimer's disease; it was tested versus placebo in the described dose-ranging ADAS-Cog study. \ue200cite\ue202turn0search7\ue202turn0search6\ue201",
        "Additional context / ambiguity: Some biomarker studies reported that talsaclidine decreased CSF A\u03b2 levels (suggesting a possible effect on APP processing/amyloid biology), but the listed trial focused on symptomatic cognitive efficacy (ADAS-Cog) over 12 weeks, so the appropriate classification for this trial is as a cognitive enhancer. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: Given the intervention type (small-molecule muscarinic agonist) and the trial's primary symptomatic cognitive endpoint, the most appropriate category is 'Cognitive enhancer'."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational agent is talsaclidine, a functionally selective muscarinic M1 receptor agonist developed as a symptomatic cognitive enhancer; the trial's primary outcome was change in ADAS\u2011Cog, indicating a focus on improving neurotransmitter-mediated cognition rather than a primary disease-modifying amyloid/tau intervention. \ue200cite\ue202turn1search0\ue202turn0search3\ue201",
        "Act: Talsaclidine is a small\u2011molecule, functionally preferential M1 muscarinic acetylcholine receptor agonist (full agonist at M1, partial at M2/M3) developed by Boehringer Ingelheim for symptomatic treatment of AD \u2014 this mechanism maps to CADRO category 'Neurotransmitter Receptors'. \ue200cite\ue202turn1search5\ue202turn1search4\ue201",
        "Additional context / ambiguity: Some biomarker studies reported that talsaclidine reduced CSF A\u03b2 (consistent with M1\u2011mediated stimulation of non\u2011amyloidogenic APP processing), which could be interpreted as an indirect amyloid-related effect; however, the described dose\u2011ranging 12\u2011week study targeted symptomatic cognitive outcomes (ADAS\u2011Cog), so the trial classification should reflect the receptor/cognitive\u2011enhancer mechanism. \ue200cite\ue202turn1search3\ue202turn1search2\ue201",
        "Reflect: Given the explicit pharmacology (muscarinic M1 receptor agonism) and the symptomatic cognitive endpoint, the most specific CADRO match is D) Neurotransmitter Receptors. The amyloid\u2011related biomarker signals are secondary/indirect and do not change this trial's primary mechanistic classification. \ue200cite\ue202turn1search0\ue202turn1search3\ue201",
        "Web search results (selected supporting sources): PubMed reports of decreased CSF A\u03b2 after talsaclidine treatment; review describing talsaclidine as an M1\u2011preferential agonist and its symptomatic development; pharmacodynamic and AD trial record (dose groups and ADAS\u2011Cog primary endpoint). \ue200cite\ue202turn1search3\ue202turn1search0\ue202turn1search5\ue202turn0search3\ue201"
    ]
}